Drug Safety

, Volume 40, Issue 6, pp 457–459 | Cite as

Medicines Save, Medicines Kill

Editorial
  • 208 Downloads

References

  1. 1.
    Onakpoya I, Heneghan C, Aronson J. Post-marketing regulation of medicines withdrawn from the market because of drug-attributed deaths: an analysis of justification. Drug Safety. 2017;40(5):431–41.Google Scholar
  2. 2.
    Mullard A. Mediator scandal rocks French medical community. Lancet. 2011;377:890–2.CrossRefPubMedGoogle Scholar
  3. 3.
    World Health Organization. The world medicines situation. Geneva: World Health Organization; 2004.Google Scholar
  4. 4.
    Pal S, Dodoo A, Mantel A, Olsson S. The world medicines situation 2011: pharmacovigilance and safety of medicines. Geneva: World Health Organization; 2011.Google Scholar
  5. 5.
    Kamal-Yanni M, Saunders P. Urgent need for WHO’s reform to prioritise core functions. Lancet. 2012;379:1878.CrossRefPubMedGoogle Scholar
  6. 6.
    La Rochelle P, Lexchin J, Simonyan D. Analysis of the drugs withdrawn from the US market from 1976 to 2010 for safety reasons. Pharm Med. 2016;20:277–89.CrossRefGoogle Scholar
  7. 7.
    Lexchin J. How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009. Open Med. 2014;8:e14–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lis Y, Roberts M, Kamble S, Guo J, Raisch D. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and Outcomes Research risk benefit management working group. Value Health. 2012;15:1108–18.CrossRefPubMedGoogle Scholar
  9. 9.
    Fain K, Daubresse M, Alexander G. The food and drug administration amendments act and postmarketing commitments. JAMA. 2013;310:202–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Lundh A, Lexchin J, Mintzes B, Schroll J, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;(2):MR000033. doi:10.1002/14651858.MR000033.pub3.
  11. 11.
    Kesselheim A, Avorn J. New, “21st century cures” legislation: speed and ease vs science. JAMA. 2017;317:581–2.CrossRefPubMedGoogle Scholar
  12. 12.
    Davis C, Lexchin J, Jefferson T, Gøtzsche P, McKee M. “Adaptive pathways” to drug authorization: adapting to industry? BMJ. 2016;354:i4437.CrossRefPubMedGoogle Scholar
  13. 13.
    Carpenter D, Zucker E, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008;358:1354–61.CrossRefPubMedGoogle Scholar
  14. 14.
    Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med. 2012;172:1680–1.CrossRefPubMedGoogle Scholar
  15. 15.
    Moore T, Singh S, Furberg C. The FDA and new safety warnings. Arch Intern Med. 2012;172:78–80.CrossRefPubMedGoogle Scholar
  16. 16.
    Auditor General of Canada. Chapter 4: regulating pharmaceutical drugs. Ottawa: Health Can; 2011.Google Scholar
  17. 17.
    Carpenter D. Reputation and power: organizational image and pharmaceutical regulation at the FDA. Princeton, NJ: Princeton University Press; 2010.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.School of Health Policy and ManagementYork UniversityTorontoCanada
  2. 2.University Health NetworkTorontoCanada
  3. 3.Department of Family and Community MedicineUniversity of TorontoTorontoCanada

Personalised recommendations